Background: SLE originates from the complex interplay between genetic, epigenetic and environmental factors but the effects of the latter remain elusive. Very few studies have examined the impact of the place of residence (urban/rural) on SLE clinical profile and outcomes. Objectives: To evaluate the effect of rural versus urban place of residency with regards to: i) SLE occurrence; ii) delay in diagnosis; iii) clinical manifestations, severity and non-reversible organ damage; iv) comorbidities and hospitalizations. Methods: We employed data from the Lupus Epidemiology & Surveillance project in Crete (750 adult SLE patients with ≥4 ACR-1997 classification criteria). Crete is a Mediterranean island with genetically stable and homogenous population in ethnicity and sociodemographic characteristics, with no significant inequalities regarding access to healthcare facilities; 61% of the inhabitants live in rural (<10,000 people) and 47% in urban areas (>10,000 people). Demographics and residency history were retrieved from face interviews. In 200 patients with exclusively urban or rural residence, a subanalysis was performed in relation to disease risk, diagnosis age, disease severity, renal and neuropsychiatric involvement, and organ damage (SLICC damage Index [SDI] ). Results: SLE prevalence (December 2013) varied across the four geographical prefectures of Crete ( Figure 1 ) and was significantly higher in urban (165/10 5 ) than rural (123/10 5 ) areas (p<0.001). The relative risk of SLE in urban versus rural regions was 2.0 (95% Confidence Interval 1.5-2.9). Notably, patients in urban regions had lower age of diagnosis (38.0±13.4 vs. 44.5±14.8 years, p=0.005) and female-to-male ratio (6.5:1 vs. 11:1) than those in rural regions. Delay >2 years between symptoms onset and SLE diagnosis occurred in 42% of patients from rural areas as compared to 32% of those from urban areas (p=0.01). Acute cutaneous lupus was more prevalent in the rural environment (83.9% vs. 72.6%, p=0.05) whereas the opposite trend was noted for discoid rash (2.3% vs. 16.8%, p=0.001). Nephritis occurred less frequently (10.3% vs. 12.4%) and neuropsychiatric disease was more prevalent (14.9% vs. 10.6%) in rural than urban patients albeit non-significantly. Prevalence of mild, moderate, and severe disease was 42%, 40%, and 18% in patients from rural areas, the respective figures being 55%, 28% and 18% in those from urban areas (p=0.12). Hospitalization due to active lupus did not differ between the two groups. At last follow-up, 45.3% of the patients living in urban and 51.9% of patients in rural areas had no organ damage (p=0.89). Concurrent allergic diseases were more frequent in urban patients (30.9% vs. 14.3%, p=0.045), particularly allergic rhinitis (8.8% vs. 2.3%, p=0.05).
Conclusions: SLE may be more prevalent in urban than rural regions and urbanization is associated with increased risk of SLE and earlier age of disease onset. Our results suggest an important effect of the environment on SLE occurrence and characteristics, which warrants further investigation. Franklyn et al.) . Clinical Remission was defined as a PGA<0.5, clinical SLEDAI=0 and no prednisone or immunosuppressants. Clinical Remission on Treatment allowed for prednisone≤5mg/day and immunosuppressant use. LLDAS was defined as a SLEDAI ≤4, PGA ≤1.0, no major organ activity, and no new activity. LLDAS on treatment allowed for prednisone use ≤7.5 mg/d and immunosuppressants. Damage was defined using the SLICC/ACR index. Results: There were 81,118 person-months observed among 2,026 patients (92% female, 53% Caucasian, 39% African-American). Table 1 shows the rates of damage, per person month, in subgroups defined by Remission or LLDAS. Damage rates were relatively low when LLDA was achieved at least 50% of the time. These rates were similar to those experienced by patients who met a more stringent treatment restriction with Remission on Treatment at least 50% of the time.
Conclusions:
The equivalence of LLDAS and DORIS remission on treatment is welcome news, as LLDAS on treatment >50% of the time is an easier goal to achieve (3 times more person-months observed in our cohort) and more realistic as a clinical trial outcome. Background: Infection is a major cause of morbidity and mortality in SLE patients. It would be helpful to have a tool to predict the risk that an individual patient with SLE will develop serious infection. Objectives: To develop a predictive risk calculator algorithm (SCORE) that assesses the probability of serious infection (i.e. leading to hospitalization) in SLE patients and to test it in an independent cohort. Methods: The SCORE was developed using data from the RELESSER (Spanish Society of Rheumatology Lupus Registry) cohort of 3658 SLE patients. A Cox regression model for repeated events (Andersen-Gill) was applied to assess which demographic and clinical factors were independently associated with increased risk of developing serious infection (Table 1) . The SCORE was then validated using retrospective data from the UCLH (University College London Hospital) cohort including 699 SLE patients. Median SCORE values were compared between sub-groups of patients using the U-Mann-Whitney test. Results: Among 699 SLE UCLH patients, 98 (14%) developed serious infection. We compared these patients with 111 SLE controls who have never suffered serious infection. The characteristics of both groups are summarized in table 2. The infection group were more likely to have suffered previous infection (P=0.001) and/or hospitalized for SLE (P<0.001) and had renal and joint disease (P=0.005). Over a quarter of the infection group died from their infection. Median (Md) SCORE at diagnosis in SLE patients with infection was 4.27 (IQR 3.18) which was significantly higher than in the control group (Md 2.55, IQR 3.79) (z=3.341; P=0.0008). Md SCORE before infection in patients was 5.3 (IQR 3.68) which was significantly higher than SCORE at diagnosis (z=-5.733; P≤0.001) in those patients. By ROC analysis, we defined three possible cut-offs to distinguish patients with and without infection. The area under the ROC curve was 0.66 (CI 95% 0.56 to 0.71). A cut-off for SCORE at diagnosis >3.18 identified patients who would develop serious infection with sensitivity (S)76.5% and specificity (SPC) 50.5%. For SCORE >3.79, S was 64.3% and SPC 57.7%. For SCORE >4.24, S was 64.3% and SPC 60.4%. Background: There has been data about pathogenic role of NLRP3 inflammasome in Sjögren's syndrome. However, linkage between their clinical features and NLRP3 inflammasome has not been clearly defined.
Objectives: The aim of this study is to identify the association of NLRP3 inflammasome with clinical features in patients with primary Sjögren's syndrome. Methods: A total 25 female patients with Sjögren's syndrome and gendermatched 25 healthy controls were consecutively enrolled. The mRNA expression for target genes including NLRP3, ASC, caspase-1, IL-1b, and IL-18 in peripheral blood mononuclear cells (PBMCs) were measured using real-time polymerase chain reaction. Serum IL-1b and IL-18 expression were also measured by ELISA method. Clinical information and disease activity and damage for Sjogren's syndrome such as EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and Sjögren's Syndrome Disease Damage Index (SSDDI) were collected at the time of enrollment. Statistical analysis were applied including Spearman's correlation coefficient and Mann-Whitney t-test. Results: Patients with Sjögren's syndrome was found to be highly expressed in mRNA IL-1b and its protein, compared to controls (p<0.001 and p=0.001, respectively). The mRNA levels of caspase-1 and ASC were significantly higher than those in controls (p=0.021 and p=0.008, respectively), but not mRNA level of NLRP3. The mRNA level of IL-1b is closely related with mRNA level of NLRP3 and ESR (r =0.549, p<0.001 and r =0.577, p=0.003, respectively Conclusions: PON3 levels are reduced and PON 3 activity is decreased in patients with SLE as compared to healthy controls, the difference was attributable to the disease itself. This may contribute to premature atherosclerosis in these patients. 
